Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- Our ability to generate product revenue will depend heavily on the success of existing products and new developments in synthetic biology, biologic drugs, and data storage.
- We incurred net losses of $208.7 million in 2024, compared to $204.6 million in 2023, indicating ongoing financial challenges.
- We currently hold 150 issued patents and over 400 pending patent applications, reflecting our commitment to innovation and intellectual property protection.
- The commercialization of liquid biopsy applications may face challenges, impacting sales if clinical value is less than anticipated and reimbursement is inadequate.
- Our manufacturing facilities in Wilsonville, Oregon, and South San Francisco, California, are critical; disruptions could significantly impact product supply and business operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1581280&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.